SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 205.01+2.1%11:33 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (11205)11/16/1997 12:30:00 AM
From: Andrew H  Read Replies (1) of 32384
 
Henry, here is an interesting report that seems to be suggesting little resistance of the HIV virus to protease inhibitors and the cocktail:

>>-report that many patients taking the new drug cocktails, known as combination therapy, for as long as 30 months show no signs of developing drug-resistant strains of HIV. They do, however, still harbor latent virus in a small number of their T cells--immune cells that are HIV's primary target--despite having undetectable blood levels of HIV.<<

sciencemag.org

Of course this is not to say that drug resistanT HIV WONT develop in these patients. However, it is encouraging. Of course the virus does survive.

Perhaps just the other side of the AP article you posted which suggested the HIV cocktail users might be split in half with 1/2 developing resistance and the other half maintaining.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext